Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics – Evaluation in biologically relevant in-vitro models

Materials Science and Engineering C(2021)10.1016/j.msec.2021.111891Source: DataRank Database

Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics – Evaluation in biologically relevant in-vitro models is a research paper published in Materials Science and Engineering C (2021). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

17 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.65)OA: closedTopics (42)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Bhuvaneshwar Vaidya ORCID,Vivek Gupta ORCID,Nishant S. Kulkarni

Live enrichment

PubMed:33579503 OpenAlex:https://openalex.org/W3120934407

National Institutes of Health

Grant: 1R15HL138606-01A1

Targeting of Apoptotic and Autophagy Pathways for Treatment of Pulmonary Arterial Hypertension (PAH)

St. John's University

FWCI

1.65

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: Elsevier TDM

publisherhttps://api.elsevier.com/content/article/PII:S0928493121000291?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0928493121000291?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.msec.2021.111891

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33579503

https://dx.doi.org/10.1016/j.msec.2021.111891

Fields of Study

Monoclonal and Polyclonal Antibodies ResearchNanoparticle-Based Drug DeliveryRNA Interference and Gene Delivery03 medical and health sciences0302 clinical medicineCarcinoma, Non-Small-Cell LungCell Line, TumorErlotinib HydrochlorideHumansLung NeoplasmsQuinacrine

MeSH Terms

Erlotinib HydrochlorideCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsQuinacrineCell Line, Tumor

Keywords

ErlotinibLung cancerMedicineDrugCombination therapyPharmacologyDrug developmentIn vitroCancerEGFR inhibitorsTyrosine-kinase inhibitorOncologyCancer researchInternal medicineEpidermal growth factor receptorBiologyNanoparticlessynergyQuinacrineNSCLCErlotinib HydrochlorideLung NeoplasmsCarcinoma, Non-Small-Cell LungCell Line, TumorHumans

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics – Evaluation in biologically relevant in-vitro models

FAIR Checklist

Authors (3)

Funding (2 grants)

Impact

Open Access

Topics